The assessment of bleeding patterns in postmenopausal women during continuous combined hormone replacement therapy: a review of methodology and recommendations for reporting of the data

References

• Ettinger B, Li D, Klein R. Continuation of post-menopausal hormone replacement therapy: comparison of cyclic versus continuous com-bined schedules. Menopause 1996;3:185–9
   Google Scholar
• Archer DF, Pickar JH, Bottiglioni F, for the Menopause Study Group. Bleeding patterns in postmenopausal women taking continuous com-bined or sequential regimens of conjugated estro-gens with medroxyprogesterone acetate. Obstet Gynecol 1994;83:686–92
   Google Scholar
• Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080–7
   Google Scholar
• Goldman GA, Kaplan B, Leiserowitz DM, Pardo Y, Amster R, Fisch B. Compliance with hormone replacement therapy in postmenopausal women. A comparative study. Clin Exp Obstet Gynecol 1998;25:18–19
   PubMedGoogle Scholar
• Hahn RG. Compliance considerations with estrogen replacement: withdrawal bleeding and other factors. Am J Obstet Gynecol 1989;161: 1854–8
   PubMed Web of Science ®Google Scholar
• Hahn RG, Nachtigall RD, Davies TC. Compli-ance difficulties with progestin-supplemented estrogen replacement therapy. J Fam Pract 1984; 18:411–14
   Google Scholar
• Nachtigall LE. Compliance with hormone replacement therapy: where we stand today. In Berg G, Hammar M, eds. The Modern Manage-ment of the Menopause: a Perspective for the 21stCentury. Carnforth, UK: Parthenon Publishing; 1993:439–43
   Google Scholar
• Nachtigall LE. Enhancing patient compliance with hormone replacement therapy at meno-pause. Obstet Gynecol 1990;75:77–835
   Google Scholar
• Wilcox JG, Hwang J, HodisSevanian A,Stanczyk FZ, Lobo RA. Cardioprotective effects of individual conjugated equine estrogens through their possible modulation of insulin resistance and oxidation of low-density lipo-protein. Fertil Steril 1997;67:57–62
   Google Scholar
• Barrett-Connor E, Slone S, Greendale G, Kritz-Silverstein D, Espeland M, Johnson SR, et al. The Postmenopausal Estrogen/Progestin Interventions study: primary outcomes in adherent women. Maturitas 1997;27:261–74
   Google Scholar
• Gibaldi M. Prevention and treatment of osteo-porosis: does the future belong to hormone replacement therapy? J Gun Pharmacol 1997;37: 1087–99
   Google Scholar
• Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992;117:1016–37
   PubMed Web of Science ®Google Scholar
• Writing Group for the PEP Trial. Effects of estro-gen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women: Postmenopausal Estrogen/Progestin Interven-tions (PEP!) Trial. J Am Med Assoc 1995;273: 199–208
   Google Scholar
• Belchetz PE. Hormonal treatment of postmeno-pausal women. N Engl J Med 1994;330:1062–71
   PubMed Web of Science ®Google Scholar
• Gallagher JC. Role of estrogens in the manage-ment of postmenopausal bone loss. Rheum Dis Clin North Am 2001;27:143–62
   PubMed Web of Science ®Google Scholar
• Betsey EM, Machin D, d'Arcangues C. The analy-sis of vaginal bleeding patterns induced by fertility regulating methods. Contraception 1986;34:253–60
   Google Scholar
• Betsey EM, Farley TMM. The analysis of men-strual bleeding patterns: a review. Contraception 1988;38:129–56
   PubMedGoogle Scholar
• Al-Azzawi F, Wahab M, Habiba M, Akkad A, Mason T. Continuous combined hormone replacement therapy compared with tibolone. Obstet Gynecol 1999;93:258–64
   Google Scholar
• Archer DF, Pickar JH. Hormone replacement therapy: effect of progestin dose and time since menopause on endometrial bleeding. Obstet Gynecol 2000;96:899–905
   PubMed Web of Science ®Google Scholar
• Archer DF, Dorin MH, Heine W, Nanavati N, Arce JC, for the Endometrium Study Group. Uterine bleeding in postmenopausal women on continuous therapy with estradiol and norethindrone acetate. Endometrium Study Group. Obstet Gynecol 1999;94:323–9
   Google Scholar
• Hammar M, Christau S, Nathorst-Böös J, Rud T, Garre K. A double-blind, randomised trial com-paring the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symp-toms. Br J Obstet Gynaecol 1998;105:904–11
   Google Scholar
• Nand SL, Webster MA, Baber R, O'Connor V. Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy. Obstet Gynecol 1998;91:678–84
   Google Scholar
• Obel EB, Munk-Jensen N, Svenstrup B, Bennett P, Micic S, Henrik-Nielsen R, et al. A two-year double-blind controlled study of the clinical effect of combined and sequential postmeno-pausal replacement therapy and steroid metabo-lism during treatment. Maturitas 1993;16:13–21
   PubMed Web of Science ®Google Scholar
• Odmark I-S, Jonsson B, Bäckström T. Bleeding patterns in postmenopausal women using contin-uous combination hormone replacement therapy with conjugated estrogen and medroxyprogester-one acetate or with 170-estradiol and norethin-drone acetate. Am J Obstet Gynecol 2001;184: 1131–8
   Google Scholar
• Archer DF, Furst K, Tipping D, Dain M-P, Vandepol C, for the CombiPatch Study Group. A randomized comparison of continuous combined transdermal delivery of estradiol—norethindrone acetate and estradiol alone for menopause. Obstet Gynecol 1999;94:498–503
   Google Scholar
• Blanc B, Cravello L, Micheletti M-C, d'Ercole C, Zartarian M. Continuous hormone replacement therapy for menopause combining nomegestrol acetate and gel, patch, or oral estrogen: a compar-ison of amenorrhea rates. Clin Ther 1998;20: 901–12
   Google Scholar
• de Ziegler D, Ferriani R, Moraes LAM, Bulletti C. Vaginal progesterone in menopause: Crinone® 4% in cyclical and constant combined regimens. Hum Reprod 2000;15( Suppl 1):149–58
   PubMedGoogle Scholar
• Gräser T, Muller A, Mellinger U, Muck AO, Lippert TH, Oettel M. Continuous-combined treatment of the menopause with combinations of oestradiol valerate and dienogest — a dose-ranging study. Maturitas 2000;35:253–61
   Google Scholar
• Mittsson LA, Bohnet HG, Gredmark T, Torhorst J, Hornig F, Hills G. Continuous, com-bined hormone replacement: randomized com-parison of transdermal and oral preparations. Obstet Gynecol 1999;94:61–5
   PubMed Web of Science ®Google Scholar
• Oosterbaan HP, van Buuren AHJAM, Schram JHN, van Kempen PJH, Ubachs JMH, van Leusden HAIM, et al. The effects of continuous combined transdermal oestrogen—progestogen treatment on bleeding patterns and the endo-metrium in postmenopausal women. Maturitas 1995;21:211–19
   PubMed Web of Science ®Google Scholar
• Rozenberg S, Caubel P, Lim PC. Constant estro-gen, intermittent progestogen vs. continuous combined hormone replacement therapy: toler-ability and effect on vasomotor symptoms. Int J Gynaecol Obstet 2001;72:235–43
   Google Scholar
• Symons J, Kempfert N, Speroff L, for the FemHRT Study Investigators. Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. Obstet Gynecol 2000;96:366–72
   Google Scholar
• Ylikorkala 0, Rozenberg S. Efficacy and toler-ability of fully transdermal hormone replacement in sequential or continuous therapy at two doses of progestogen in postmenopausal women. Maturitas 2000;37:83–93
   Google Scholar